Fundsmith, an investment management firm, released its 2025 investor letter focusing on global equities. T Class Accumulation shares returned 0.8% in 2025 compared to the MSCI World Index’s 12.8%. Fund has outperformed index by 1.7% p.a. since inception. Underperformance in 2025 due to index concentration, growth of Index Funds, and weak dollar.

In Q4 2025, Fundsmith Equity Fund highlighted Zoetis Inc. (NYSE: ZTS), a company involved in animal health products. Stock closed at $127.17 per share on January 9, 2026. With a market cap of $56.36 billion, Zoetis Inc. (NYSE: ZTS) saw a one-month return of 7.17% and a 52-week loss of 22.13%.

Fundsmith Equity Fund sold stakes in Brown-Forman and PepsiCo, purchased stakes in Zoetis Inc. (NYSE:ZTS), EssilorLuxottica, Intuit, and Wolters Kluwer in 2025. Zoetis is a leading veterinary pharmaceutical company tapping into pet healthcare growth. Despite concerns, Zoetis’s drug Librela remains popular. Is Zoetis a unique dividend play in 2025?

Zoetis Inc. (NYSE: ZTS) not among 30 Most Popular Stocks Among Hedge Funds. 72 hedge fund portfolios held Zoetis at the end of Q3 2025, down from 75 in the previous quarter. Zoetis reported $2.4 billion in revenue in Q3 2025, growing 1% on a reported basis and 4% on an organic operational basis. Consider AI stocks for greater potential.

Read more at Yahoo Finance: Harnessing Growth with Minimum Rivalry